EichorEICHOR
Location: Sendai Synced from ClinicalTrials.gov · August 09, 2026

Clinical studies recruiting near Sendai

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer
Phase 3 · Miyagi Cancer Center · National Cancer Center Hospital East · NCT04288999A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Hav
Phase 3 · Tohoku University Hospital · Pfizer · NCT05020236Observational Study Protocol: LIVER-R
Phase N/A · Research Site · AstraZeneca · NCT06252753A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Phase 3 · Tohoku University Hospital · Eli Lilly and Company · NCT07218380Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Phase 3 · Tohoku University Hospital · Daiichi Sankyo · NCT07022483A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Phase 3 · Tohoku Medical and Pharmaceutical University Hospital · Takeda · NCT06747351A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line
Phase 3 · Tohoku University Hospital ( Site 1901) · Merck Sharp & Dohme LLC · NCT06136559A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurr
Phase 2 · Tohoku University Hospital · Yonsei University · NCT06023862Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Phase 3 · Tohoku University Hospital ( Site 3422) · Merck Sharp & Dohme LLC · NCT06393374This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in
Phase 3 · Sendai Kousei Hospital · Pfizer · NCT06758401A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have P
Phase 2 · Tohoku University Hospital · Pfizer · NCT07073820A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
Phase 3 · National University Corporation Tohoku University Tohoku Uni · Takeda · NCT06671496A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carbop
Phase 3 · Tohoku University Hospital · Hoffmann-La Roche · NCT06793215Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiov
Phase 3 · KKR Tohoku Kosai Hospital · Amgen · NCT07037433Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Phase 3 · Clinical Study Site · Summit Therapeutics · NCT07228832A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Pati
Phase 2 · Novartis Investigative Site · Novartis Pharmaceuticals · NCT06581198A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic
Phase 3 · Research Site · AstraZeneca · NCT06868277A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Dia
Phase 3 · Sendai City Hospital - Asutonagamachi · Eli Lilly and Company · NCT07222332A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathie
Phase 3 · Tohoku University Hospital · Pfizer · NCT05895786A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previ
Phase 3 · Sendai Kousei Hospital · Pfizer · NCT07144280A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants Wit
Phase 3 · Sendai Kousei Hospital ( Site 3805) · Merck Sharp & Dohme LLC · NCT06077760EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Phase 3 · Tohoku University Hospital · Boehringer Ingelheim · NCT06531824A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Phase 3 · Tohoku University Hospital · Pfizer · NCT07029828Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Phase 3 · Ogura Orthopedics Surgery · Eli Lilly and Company · NCT07353931Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic Syndrome
Phase 3 · Tohoku University Hospital · Shoichi Maruyama MD PhD · NCT05914155A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Ad
Phase 2 · Tohoku University Hospital /ID# 276344 · AbbVie · NCT07196644Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Phase N/A · Miyagi Children's Hospital · Novartis Pharmaceuticals · NCT04174157A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Phase 3 · Japan Community Health care Organization Sendai Hospital · Takeda · NCT06963827A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR
Phase 2 · Sendai Kousei Hospital · Taiho Oncology, Inc. · NCT05967689A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel
Phase 3 · Sendai Kousei Hospital /ID# 253350 · AbbVie · NCT04928846
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.